Inhalations Sciences: US patent on XposeALI extended until 2034

(Stockholm October 25, 2021) Inhalation Sciences’ US patent protection on its in vitro Cell Culturing module XposeALI[®] has been extended until 2034. CEO Manoush Masarrat: “The US is a major market with enormous potential. XposeALI[®] offers US developers of inhaled pharmaceuticals an important competitive advantage.”

ISAB’s first US patent application was submitted on September 25^th, 2013, when it was approved up until December 1^st, 2020 under the number 11054414. The patent has now been extended and is valid until 2034.

ISAB’s XposeALI^® is a highly innovative and leading instrument within in vitro cell culturing that combines aerosol capability with 3D cell models cultured in an Air Liquid Interface. On October 12^th, ISAB announced that XposeALI^® will be used to test a Mars dust surrogate for the European Space Agency in a research project with the Institute for Environmental Medicine (IMM) at Karolinska Institutet (KI) in Stockholm, Sweden.

ISAB CEO Manoush Masarrat: “The US is a major market with enormous potential. The outstanding capabilities and precision of XposeALI^® offers developers of inhaled pharmaceuticals in the US exceptional precision, reduced risk and a major competitive advantage throughout coming decades.”

For more information on Inhalation Sciences, please contact: Manoush Masarrat, CEO E-mail: Manoush.masarrat@inhalation.se Mobile: +46 (0)73 628 9153